Summary
Danaher Corporation's (DHR) Q2 2017 report shows continued growth driven by acquisitions and core business performance, with overall sales increasing by 6.5% for the quarter. The company's high-growth markets, representing approximately 31% of total sales, were particularly strong, growing at a mid-single digit rate, led by China and India. However, the Diagnostics segment experienced a significant hit to its operating profit margin due to restructuring charges related to discontinuing a molecular diagnostic product line, resulting in a $76 million pretax charge. Despite this, the company maintains a positive outlook for continued sales growth in the remainder of 2017, although it remains cautious about macroeconomic and geopolitical uncertainties. Financially, DHR demonstrated solid operating cash flow, though it slightly decreased year-over-year. The company actively managed its debt, issuing yen and euro-denominated notes to repay commercial paper. Despite the restructuring charges and some segment-specific headwinds, Danaher's diversified business model and strategic investments in innovation and globalization position it for ongoing development. Investors should monitor the integration of recent acquisitions, particularly Cepheid, and the ongoing restructuring impact on margins.
Financial Highlights
52 data points| Revenue | $4.51B |
| Cost of Revenue | $2.03B |
| Gross Profit | $2.48B |
| R&D Expenses | $283.30M |
| SG&A Expenses | $1.52B |
| Operating Income | $676.70M |
| Interest Expense | $40.70M |
| Net Income | $557.30M |
| EPS (Basic) | $0.80 |
| EPS (Diluted) | $0.79 |
| Shares Outstanding (Basic) | 695.40M |
| Shares Outstanding (Diluted) | 705.40M |
Key Highlights
- 1Total sales grew by 6.5% for the three months ended June 30, 2017, compared to the prior year, with existing businesses ('core sales') contributing 2.0% and acquisitions adding 6.0%.
- 2High-growth markets continue to be a key driver, with sales from existing businesses in these regions growing at a mid-single digit rate, led by China and India.
- 3The Diagnostics segment faced significant headwinds, with operating profit margins decreasing substantially (760 bps for the quarter) due to a $76 million pretax charge related to discontinuing a molecular diagnostic product line.
- 4Danaher made strategic acquisitions totaling $94 million in the first six months of 2017, complementing its Life Sciences and Environmental & Applied Solutions segments.
- 5Foreign currency exchange rates negatively impacted reported sales by approximately 1.5% year-over-year, but this impact is expected to be negligible for the full year 2017.
- 6Operating cash flow from continuing operations was $1.57 billion for the first six months of 2017, a slight decrease of 1% compared to the same period in 2016.
- 7The company actively managed its debt by issuing yen and euro-denominated notes, using the proceeds to repay commercial paper and other borrowings.